It's no mystery. History tells us that President Trump’s executive order calling for the MMR to be split into separate shots could do real harm.

Not long after guidelines shifted to considering statin therapy as early as age 30, new research from France suggests there may be no harm in stopping the cholesterol-lowering drugs at age 75 in ...

President Donald Trump’s administration said that Medicaid will stop paying for gender-affirming surgeries and hormone treatments for transgender minors and the state Children’s Health Insurance ...

The White House says Trump’s recent executive order is aimed at restoring trust in vaccines. It will do the opposite, writes an epidemiologist.

On Monday, Trump signed an order that sought to unilaterally change the federal government’s approach to vaccinating children: recommending fewer shots, spreading them over longer periods, and doing ...

As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...